Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more
Zelira Therapeutics Limited (ZLDAF) - Total Assets
Latest total assets as of June 2025: $1.30 Million USD
Based on the latest financial reports, Zelira Therapeutics Limited (ZLDAF) holds total assets worth $1.30 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zelira Therapeutics Limited - Total Assets Trend (2015–2025)
This chart illustrates how Zelira Therapeutics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zelira Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Zelira Therapeutics Limited's total assets of $1.30 Million consist of 47.2% current assets and 52.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $4.69K | 0.4% |
| Inventory | $477.91K | 36.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $520.63K | 40.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Zelira Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zelira Therapeutics Limited's current assets represent 47.2% of total assets in 2025, a decrease from 81.6% in 2015.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 79.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 40.0% of total assets.
Zelira Therapeutics Limited Competitors by Total Assets
Key competitors of Zelira Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Zelira Therapeutics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zelira Therapeutics Limited generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zelira Therapeutics Limited is currently not profitable relative to its asset base.
Zelira Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.60 | 2.73 |
| Quick Ratio | 0.02 | 0.42 | 2.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.98 Million | $ -2.83 Million | $ 1.16 Million |
Zelira Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Zelira Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 1.44 |
| Asset Growth Rate (YoY) | -74.9% |
| Total Assets | $1.30 Million |
| Market Capitalization | $1.87 Million USD |
Valuation Analysis
Above Book Valuation: The market values Zelira Therapeutics Limited's assets above their book value (1.44 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Zelira Therapeutics Limited's assets decreased by 74.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zelira Therapeutics Limited (2015–2025)
The table below shows the annual total assets of Zelira Therapeutics Limited from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $1.30 Million | -74.91% |
| 2024-06-30 | $5.18 Million | -84.71% |
| 2023-06-30 | $33.89 Million | -10.11% |
| 2022-06-30 | $37.70 Million | -4.23% |
| 2021-06-30 | $39.37 Million | +9.99% |
| 2020-06-30 | $35.79 Million | +918.11% |
| 2019-06-30 | $3.52 Million | -44.33% |
| 2018-06-30 | $6.31 Million | -20.75% |
| 2017-06-30 | $7.97 Million | +9003.45% |
| 2016-06-30 | $87.52K | -72.11% |
| 2015-06-30 | $313.80K | -- |